Circulating Adiponectin Levels Following Treatment Can Predict Late Clinical Outcomes in Chronic Heart Failure.
BACKGROUND
Circulating adiponectin concentration increases in patients with chronic heart failure (HF). We sought to explore the prognostic value of temporal changes in adiponectin concentration following treatment for chronic HF.


METHODS
Serum adiponectin levels were measured at baseline and after a 3-month anti-failure treatment in 124 patients with symptomatic chronic systolic HF. Major adverse cardiac events (MACE) including death, heart transplantation, or hospitalization with worsening HF during a median follow-up period of 752 days were determined.


RESULTS
Univariate and multivariate analysis showed that high levels of adiponectin after a 3-month treatment were associated with a 3.8-fold increased risk of MACE (p = 0.03), independent of amino-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. Moreover, the combining of circulating levels of adiponectin with NT-proBNP provided independent and additional prognostic value in identifying high risk patients with MACE during follow-up.


CONCLUSIONS
Changes in adiponectin and NT-proBNP over time provide prognostic information. When adiponectin is used in conjunction with NT-proBNP in chronic HF, the prognostic value may be better than if each biomarker is used separately.
Heart Center, Cheng Hsin General Hospital.
Ho-Ping
HP
Yu
Heart Center, Cheng Hsin General Hospital; ; Institute of Clinical Medicine.
Hsu-Lung
HL
Jen
Heart Center, Cheng Hsin General Hospital; ; Faculty of Medicine; ; Cardiovascular Research Centre, National Yang-Ming University, School of Medicine, Taipei, Taiwan.
Wei-Hsian
WH
Yin
Heart Center, Cheng Hsin General Hospital.
Jeng
J
Wei
Adiponectin; Chronic heart failure; Natriuretic peptide; Prognosis